With inflation, rate expectations and growth signals pulling markets in different directions, many investors are looking for stocks where earnings are expected to grow and balance sheets are not overly stretched. The Healthy high growth potential screener focuses on companies that analysts expect to deliver strong earnings growth over the next 3 years while still meeting basic financial health criteria. That combination can help you focus on businesses that are not only targeting higher profits but also have an acceptable financial position. Below, the article will highlight 3 stocks from this screener for your watchlist.

Butterfly Network (BFLY)

Overview: Butterfly Network develops handheld and cart-based ultrasound devices that connect to smartphones, tablets, and hospital systems, aiming to make whole-body imaging more portable and accessible for clinicians. It also offers software such as Compass AI and ScanLab, along with veterinary and bladder-focused products, and sells primarily through direct sales, distributors, and online channels in the US and abroad.

Operations: Butterfly Network generates about US$102.9 million in revenue from its AI-enhanced personal ultrasound solution, with roughly US$81.8 million from the United States and US$21.2 million from international customers.

Market Cap: US$2.10b

Butterfly Network stands out in this screener because it combines handheld ultrasound hardware with AI tools like Compass AI and ScanLab, which are designed to streamline workflows and support clinicians at the bedside. The stock currently trades on a very high P/S multiple and the share price has been highly volatile, so expectations appear demanding. Recent collaborations on full body and neuroimaging platforms, fresh FDA clearance for an automated gestational age tool, and a debt free balance sheet with a multiyear cash runway are notable features of the current setup, even as funding relies on external borrowing and management remains relatively new.

Butterfly Network’s mix of AI tools, handheld hardware and a debt free balance sheet has investors debating whether the high P/S multiple is justified, so it is worth reading the 1 key reward and 2 important warning signs (1 is major!)

ARS Pharmaceuticals (SPRY)

Overview: ARS Pharmaceuticals develops and commercializes neffy, a needle free intranasal epinephrine treatment designed to provide rapid relief in severe allergic reactions and anaphylaxis, offering an alternative to traditional injectable auto injectors for patients in the United States and internationally.

Operations: ARS Pharmaceuticals generates about US$99.0 million in revenue from its pharmaceuticals business, with roughly US$81.9 million attributed to the United States and the remainder reflected in segment adjustments.

Market Cap: US$796.4 million

ARS Pharmaceuticals offers a focused way to gain exposure to demand for fast, needle free treatment of severe allergies through neffy, with expanding pediatric, school and international access indicating a potentially larger user base over time. At the same time, the company currently depends heavily on this single product, is still reporting sizeable losses such as a Q1 2026 net loss of US$60.6 million, and funds itself entirely through higher risk external capital, so execution on payer coverage and cost control is critical. The company is also pursuing new indications, such as chronic spontaneous urticaria, and overseas launches, which could change its earnings profile if these initiatives proceed as planned.

ARS Pharmaceuticals is working to turn a single high stakes product into a broader allergy platform story, so it is worth seeing how analysts frame the growth profile and payer execution in the analyst forecasts for ARS Pharmaceuticals

Iovance Biotherapeutics (IOVA)

Overview: Iovance Biotherapeutics develops and commercializes personalized cell therapies, including its approved Amtagvi treatment and Proleukin, to target metastatic melanoma and other solid tumors in the United States and internationally.

Operations: Iovance Biotherapeutics generates about US$285.6 million in revenue from developing and commercializing autologous tumor infiltrating lymphocyte therapies, with roughly US$281.0 million from the United States and US$4.6 million from the rest of the world.

Market Cap: US$1.88b

Iovance Biotherapeutics is attracting attention because Amtagvi is already commercial, revenue guidance for Amtagvi and Proleukin has been set in the hundreds of millions of dollars, and recent approvals in the US, Canada, and now Australia point to growing patient reach. At the same time, the company is still loss making, relies on higher risk external funding, and plans to increase its authorized share count, so dilution and execution risk are front of mind. With analysts expecting strong revenue and earnings growth, a pipeline of next generation TIL products like IOV-5001, and ongoing work to improve manufacturing efficiency, Iovance presents a combination of notable growth prospects and meaningful risks that may warrant closer examination of the details behind those forecasts.

Iovance Biotherapeutics is trying to turn early TIL traction into a larger solid tumor platform, so reviewing the analyst forecasts for Iovance Biotherapeutics can help you see where expectations may be stretching the story or still underestimating it.

The three stocks covered here are only a starting point. The full Healthy high growth potential screener surfaced 251 more companies where analysts see strong earnings potential alongside acceptable financial positions. Use Simply Wall St to identify and analyze the specific catalysts, risk profiles and growth narratives that matter to you so you can focus on the highest conviction ideas in this Healthy high growth potential theme.

Take Control of Your Investment Journey

If Butterfly Network or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Today’s Ideas?

Stocks can move from quiet to breakout fast, and the strongest setups rarely stay under the radar for long. Scan these fresh ideas before momentum is fully caught, and consider them while they are still developing.

• Spot upcoming cash generators before momentum really builds by scanning a curated 44 high quality undervalued stocks that pairs quality fundamentals with prices that still look reasonable.
• Target resilient performers that aim to keep surprises in check using a hand picked 71 resilient stocks with low risk scores so you stay focused while others react late.
• Review a filtered 29 robotics and automation stocks built around companies linked to long term productivity and efficiency trends in automation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.